The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 801-806

  Rasmussen, Vibeke Guldbrand ^a   Østergaard, Karen ^a   Dupont, Erik ^a   Poulsen, Steen Hvitfeldt ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Dopamine agonist; Ergolines; Fibrosis; Heart valve; Parkinson

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART VALVE REGURGITATION; HUMAN; LUNG ARTERY PRESSURE; META ANALYSIS; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

DATABASES, FACTUAL; DOPAMINE AGONISTS; HEART VALVE DISEASES; HUMANS; MODELS, STATISTICAL; OBSERVATION; PARKINSON DISEASE; RISK FACTORS;

EID: 79955078728     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23470     Document Type: Review

References (40)

1. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77: 1280-1286.
2. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB, Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-304.
3. Chung EJ, Yoon WT, Kim JY, Lee WY. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide. Mov Disord 2006; 21: 586-587.
4. Dewey RB, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007; 64: 377-380.
5. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003; 78: 730-731.
6. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-662.
7. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002; 10: 334-336.
8. Van CG, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-861.
9. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005; 80: 1016-1020.
10. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
11. Flaherty KR, Bates JR. Mitral regurgitation caused by chronic ergotamine use. Am Heart J 1996; 131: 603-606.
12. Mason JW, Billingham ME, Friedman JP. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 1977; 56: 889-890.
13. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117: 50-52.
14. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000; 57: 75-81.
15. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000; 9: 256-260.
16. Xu J, Jian B, Chu R, et al. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002; 161: 2209-2218.
17. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-2841.
18. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63: 1223-1229.
19. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
20. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-822.
21. Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 2007; 64: 1721-1726.
22. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 2007; 22: 1936-1942.
23. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16: 777-802.
24. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-662.
25. Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 2007; 22: 234-238.
26. Kenangil G, Ozekmekci S, Koldas L, Sahin T, Erginoz E. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 2007; 109: 350-353.
27. Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006; 21: 1261-1264.
28. Oeda T, Masaki M, Yamamoto K, et al. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm 2009; 116: 171-178.
29. Ozer F, Tiras R, Cetin S, et al. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both. J Clin Neurosci 2009; 16: 83-87.
30. Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006; 21: 1109-1113.
31. Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med 2008; 263: 90-98.
32. Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol 2007; 254: 1575-1578.
33. Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord 2009; 24: 344-349.
34. Van CG, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-1183.
35. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67: 1225-1229.
36. Yamashiro K, Komine-Kobayashi M, Hatano T, et al. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 2008; 23: 935-941.
37. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.
38. Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007; 28: 2156-2162.
39. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616.
40. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870-874.